Having trouble accessing articles? Reset your cache.

Aug. 8 Company Quick Takes: Amarin tumbles on Vascepa update; plus Alexandria, Cambrex, Kala and miRagen

FDA panel for Vascepa means likely delay
Amarin Corp. plc (NASDAQ:AMRN) said it expects FDA to extend the PDUFA date for Vascepa icosapent ethyl to late December from Sept. 28 after the agency scheduled

Read the full 334 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE